Dendle Claire, Polkinghorne Kevan R, Mulley William R, Gan Poh-Yi, Kanellis John, Stuart Rhonda L, Thursky Karin, Holdsworth Stephen R
Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
Transpl Infect Dis. 2019 Jun;21(3):e13076. doi: 10.1111/tid.13076. Epub 2019 Apr 22.
The aim of this study was to determine whether a composite score of simple immune biomarkers and clinical characteristics could predict severe infections in kidney transplant recipients.
We conducted a prospective study of 168 stable kidney transplant recipients who underwent measurement of lymphocyte subsets, immunoglobulins, and renal function at baseline and were followed up for 2 years for the development of any severe infections, defined as infection requiring hospitalization. A point score was developed to predict severe infection based on logistic regression analysis of factors in baseline testing.
Fifty-nine (35%) patients developed severe infection, 36 (21%) had two or more severe infections, and 3 (2%) died of infection. A group of 19 (11%) patients had the highest predicted infectious risk (>60%), as predicted by the score. Predictive variables were mycophenolate use, graft function, CD4+, and natural killer cell number. The level of immunosuppression score had an area under the receiver operating curve of 0.75 (95% CI: 0.67-0.83).
Our level of immunosuppression score for predicting the development of severe infection over 2 years has sufficient prognostic accuracy for identification of high-risk patients. This data can inform research that examines strategies to reduce the risks of infection.
本研究旨在确定简单免疫生物标志物和临床特征的综合评分是否能够预测肾移植受者发生严重感染的情况。
我们对168例稳定的肾移植受者进行了一项前瞻性研究,这些受者在基线时接受了淋巴细胞亚群、免疫球蛋白和肾功能的检测,并随访2年以观察是否发生任何严重感染,严重感染定义为需要住院治疗的感染。基于基线检测因素的逻辑回归分析,制定了一个预测严重感染的评分。
59例(35%)患者发生了严重感染,36例(21%)发生了两次或更多次严重感染,3例(2%)死于感染。根据该评分预测,有19例(11%)患者具有最高的感染风险(>60%)。预测变量为霉酚酸酯的使用、移植肾功能、CD4+细胞以及自然杀伤细胞数量。免疫抑制评分水平在受试者工作特征曲线下的面积为0.75(95%CI:0.67 - 0.83)。
我们用于预测2年内严重感染发生情况的免疫抑制评分水平对于识别高危患者具有足够的预后准确性。该数据可为研究降低感染风险的策略提供参考。